NAUT nautilus.bio: Bozor kapitallashuvining balans qiymatiga nisbati

Nautilus Bio (NAUT) kompaniyasining rasmiy ramzlari

Ushbu narxlar grafigi oqsil tahlili vositalarini ishlab chiqishga e'tibor qaratgan Nautilus Biotechnology (NAUT) kompaniyasining narxlar dinamikasini aks ettiradi. Nautilus Biotechnology (NAUT) raqamli genetika nishasini egallash uchun laboratoriyalarda o'z IT yechimlari mavjudligini kengaytirishni maqsad qilgan bo'lib, asosiy ko'rsatkich 2.83 darajasida turibdi. Biroq, innovatsiyalarning sekin joriy etilishi va dominant ishtirokchilarning bosimi rivojlanishga to'sqinlik qilmoqda. Katta miqdordagi R&D xarajatlari va past daromadlar likvidlik tanqisligi xavfini yuzaga keltirmoqda.

nautilus.bio (NAUT): Kapitallashuvning balans qiymatiga nisbati 04.07.2022dan 28.10.2026gacha

NAUT (Nautilus Biotechnology): tahliliy kesimlar va indikatorlar boʻyicha maʼlumotlar

- narx va narxlar bo'yicha konsensus prognoz:
Aksiya kotirovkalari nautilus.bio|NAUT - Tahlilchilarning prognoz narxlari
- bozor kapitallashuvi bo'yicha ma'lumotlar:
Bozor kapitallashuvi Nautilus Biotechnology Inc|NAUT - Biznes qiymati
- balans kapitallashuvi bo'yicha ma'lumotlar:
Bitta aksiya uchun sof aktivlar Nautilus Biotechnology|NAUT - Buxgalteriya kapitallashuvi|Bozor kapitallashuvining balans qiymatiga nisbati nautilus.bio|NAUT - Kompaniyaning umumiy aktivlari
- qarz va likvidlik bo'yicha ma'lumotlar:
Qarzning xususiy kapitalga nisbati Nautilus Biotechnology|NAUT - Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi|Qisqa muddatli qarzning kapitalga nisbati nautilus.bio|NAUT - Kompaniyaning jamlangan qarzlari|Qarzning balans qiymatiga nisbati Nautilus Biotechnology Inc
Kompaniyaning asosiy tahlili:Nautilus Biotechnology, Inc. - NAUT
Nautilus Biotechnology asosiy tovari

Innovatsion oqsil tahlili platformasi Nautilus Biotechnology (NAUT) iqtisodiy sikllarga kam bog'liqlikni namoyish etadi, ammo ventura kapitalining mavjudligiga sezgir bo'lib qolmoqda. Bozor qiymatining buxgalteriya qiymatiga nisbati aksiyalar bozoridagi baholashning kompaniyaning sof aktivlaridan yuqoriligini o'lchaydi. Bu yerda yuqori koeffitsient joriy kapitaldan ko'ra ko'proq kelgusidagi R&D ga bo'lgan bozor kutuvlarini aks ettiradi. Bozor kapitalizatsiyasining buxgalteriya qiymatiga nisbati dinamikasini tahlil qilish orqali investor haddan tashqari ko'p to'lov qilish xavfini baholaydi. Ushbu ko'rsatkich kompaniyaning moliyaviy zarbalarga chidamlilik darajasini belgilaydi.

Asosiy raqobatchilar

TEM - Kapitallashuvning sof aktivlarga nisbati|qiagen.com (QGEN) - Bozor kapitallashuvining balans qiymatiga multiplikatori|Bozor kapitallashuvining balans qiymatiga nisbati Ionis (IONS)|Kapitallashuvning balans qiymatiga nisbati RGEN|Bozor qiymatining balans qiymatiga nisbati Avidity RNA|Kapitallashuvning balans qiymatiga nisbati CRISPR (CRSP)|Bozor kapitallashuvining balans qiymatiga nisbati WGS (GeneDx Holdings Corp.)|ultragenyx.com - Bozor kapitallashuvining balans qiymatiga nisbati|Beam Therapeutics (BEAM) - Bozor qiymatining balans qiymatiga nisbati|SRPT - Kapitallashuvning balans qiymatiga nisbati|TWST: Bozor kapitallashuvining balans qiymatiga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati 10x|NTLA (Intellia Therapeutics) - Kapitallashuvning sof aktivlarga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati stoketherapeutics.com (STOK)|Kapitallashuvning sof aktivlarga nisbati BioLife Solutions|Bozor kapitallashuvining balans qiymatiga multiplikatori Wave Life Sciences Ltd (WVE)|Bozor kapitallashuvining balans qiymatiga nisbati MAZE|Sionna Corp - Balans qiymatiga nisbatan bozor kapitallashuvi|PRME - Bozor qiymatining balans qiymatiga nisbati|tayshagtx.com (TSHA) - Bozor qiymatining balans qiymatiga nisbati|QURE: Kapitallashuvning sof aktivlarga nisbati|MGTX (MeiraGTx Holdings) - Bozor kapitallashuvining balans qiymatiga nisbati|RGNX: Bozor qiymatining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor kapitallashuvi Solid Corp (SLDB)|Ocugen, Inc. (OCGN) - Kapitallashuvning sof aktivlarga nisbati|Balans qiymatiga nisbatan bozor qiymati pacb.com (PACB)|Bozor kapitallashuvining balans qiymatiga nisbati Benitec Biopharma BNTC|Bozor qiymatining balans qiymatiga nisbati Design Therapeutics Inc DSGN|Bozor kapitallashuvining balans qiymatiga nisbati RCKT (Rocket Pharmaceuticals Inc)|FDMT: Balans qiymatiga nisbatan bozor kapitallashuvi|Bozor qiymatining balans qiymatiga nisbati LXEO|Bozor qiymatining balans qiymatiga koeffitsiyenti Korro Bio|Editas Medicine (EDIT) - Kapitallashuvning sof aktivlarga nisbati|Bozor kapitallashuvining balans qiymatiga multiplikatori Silence Therapeutics PLC|ProQR Therapeutics N.V. - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga koeffitsiyenti codexis.com (CDXS)|Sangamo Therapeutics - Bozor kapitallashuvining balans qiymatiga nisbati|Kapitallashuvning sof aktivlarga nisbati metagenomi.co MGX|Bozor kapitallashuvining balans qiymatiga nisbati Precision BioSciences (DTIL)|GBIO: Balans qiymatiga nisbatan bozor qiymati|Bozor qiymatining balans qiymatiga nisbati Boundless Bio, Inc|XCUR (Exicure) - Kapitallashuvning balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga nisbati IMNN (Imunon Inc)|Bozor qiymatining balans qiymatiga koeffitsiyenti PHIO|Bozor qiymatining balans qiymatiga nisbati Mustang Bio, Inc. (MBIO)|Bozor qiymatining balans qiymatiga nisbati RNAZ (transcodetherapeutics.com)|BNGO: Bozor qiymatining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga koeffitsiyenti Applied DNA Corp APDN|Bozor kapitallashuvining balans qiymatiga nisbati BLUE|ImmunoPrecise Antibodies (IPA) - Bozor qiymatining xususiy kapitalga nisbati|Kapitallashuvning sof aktivlarga nisbati OMGA|OMIC (Singular Genomics Systems, Inc.) - Bozor qiymatining balans qiymatiga koeffitsiyenti|Bozor qiymatining balans qiymatiga nisbati Regulus Therapeutics Inc (RGLS)|Kapitallashuvning balans qiymatiga nisbati Syros Pharmaceuticals, Inc|Bozor kapitallashuvining balans qiymatiga nisbati TBIO|Bozor kapitallashuvining balans qiymatiga nisbati traconpharma.com TCON|Kapitallashuvning sof aktivlarga nisbati UBX (Unity Biotechnology, Inc.)